Opinion|Videos|September 30, 2024
Factors to Consider When Switching Therapies
The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When is transitioning to a new therapeutic option considered, and what factors influence the decision between dose modification and switching therapies in chronic lymphocytic leukemia treatment?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
Could CAR T Therapy Become Adjustable After Infusion?
3
The Value of Self-Monitoring Blood Glucose Tools in Preventing and Reducing Prediabetes and Diabetes-Related Complications
4
Using CKDintercept to Build Interdisciplinary Kidney Care
5